STUDresearch · Peptide
Cardiogen
Also known as
AEDR · Ala-Glu-Asp-Arg · H-Ala-Glu-Asp-Arg-OH · AEDR tetrapeptide · heart bioregulator · cardiac bioregulator peptide · Cardiogen peptide · Khavinson AEDR · Khavinson heart tetrapeptide · cardiac Cytogen (synthetic class talk) · T-30 (vendor shorthand, inconsistent) · AED (vendor shorthand — sometimes confuses sequence count) · PubChem CID 11583989 (listed on secondary research pages)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Mixed
Oral / Sublingual / SubQ
Longevity & bioregulators
Cardiac-tissue research and whole-body community use; tissue selectivity does not establish targeted delivery.
What people say
Cardiogen is the synthetic AEDR tetrapeptide discussed as a heart bioregulator for cardiovascular aging and recovery. It is not Chelohart's animal-heart extract and it is not a proven treatment for heart disease.
Doses people talk about
All rows preserve community or vendor-chart ranges. No trial-established human dose or route equivalence was located.
How it may feel
Reports are inconsistent: the inspected thread includes one bedtime report of high resting heart rate and another comment describing lower heart rate and blood pressure, while the preserved profile also records little-or-nothing reports. Course-level endurance or cardiac-comfort claims remain anecdotal and stack-confounded.
Oral short-course charts10–20 mg/day for about 10 days
Khavinson-style oral charts; a convention, not a dose-ranging result.
Longer oral calendar10 mg × 10 days every ~6 months, or 20 mg/day × 20 days every ~3 months
Preventive-versus-aggressive marketing language, not evidence of efficacy.
Lower injectable charts200–500 mcg/day or 0.2–2 mg/day SubQ for about 10–20 days
Two overlapping community chart clusters; neither establishes a safe or optimal human amount.
Higher or intermittent injectable charts1–10 mg/day, or 10–20 mg every 3–7 days
Divergent vendor and secondary charts that conflict with lower daily traditions.
Other divergent charts10 mg EOD, 5–20 mg/day, or 200→500 mcg/day ramps up to 12 weeks
Examples of chart variance, not a personal progression.
Half-life & effect duration
- Half-life in the body
- Vendor estimatesAbout 30–75 seconds, or multi-hour estimates; conflicting reports
- Felt duration people report
- Bedtime accountHigher resting heart rate overnight
- Morning accountLower heart rate and blood pressure reported
Cycles people discuss
Classic charts use 10–20-day blocks; other sources stretch to 2–6 weeks or 12-week microdose ramps, with re-runs every 3–6 months. These are competing traditions, not validated maintenance schedules.
Timing
Morning oral, sublingual and injectable placement appears in charts, but no measured AEDR half-life supports those intervals. Claimed effects across days or weeks are downstream anecdotes, not evidence that the peptide remains in circulation.
Stacks
Heart-plus-vessel and multi-organ kits are common framing. Vesugen, pineal, thymus, mitochondrial and repair agents can all share credit, so stack reports are weak evidence for Cardiogen alone.
Watch for
Self-treatment risk: Not a substitute for chest pain, arrhythmia, heart failure, post-MI care, or uncontrolled hypertension workup — emergency symptoms need real medicine, not a bioregulator course.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A measured AEDR half-life was not located in the reviewed evidence ledger.
Daily and intermittent schedules coexist in secondary charts, but schedule repetition does not measure clearance.
The ledger is a secondary audit; its database searches were not independently reproduced in full during this pass.
- Vialog Cardiogen evidence ledger (opens in a new tab)Evidence ledger lines 102–123, especially What is not known lines 109–115; references lines 133–150.Secondary evidence audit rather than a primary PK study; its stated PubMed, Crossref, ClinicalTrials.gov and WHO ICTRP searches were not independently reproduced in full during this pass.
Felt duration people report
The inspected reports do not establish a dependable single-dose felt duration.
One bedtime user described overnight high resting heart rate, a possible timing difference, and stopping on day 12; another commenter described lower heart rate and blood pressure with morning use.
Self-report, unverified product identity, co-use and opposite experiences prevent causal or population-level timing inference.
- Cardiogen bioregulator - high RHR? (opens in a new tab)Original post lines 16–25; same-author follow-ups lines 81–114 and 119–133 in the content opened 2026-09-06.Single detailed self-report with HGH and SS-31 co-use, uncertain product identity and no stated route; another commenter reports the opposite direction of heart-rate and blood-pressure change.
What people say
- Endurance / training talk: Easier aerobic work, less cardio fatigue, or better oxygen-use feel over a short course — confounded by training, sleep, stimulants, and stacks. Common in PED/hard-training writeups. anecdote
- BP comfort: Mild subjective pressure-stability notes; some wellness blogs claim ~5–15 mmHg systolic / ~3–10 mmHg diastolic ranges — marketing-grade figures without a clear modern Western RCT package for pure AEDR, and not a hypertension-drug replacement. forum
- PED / stimulant recovery narrative: Hard-training and post-oral/SARM circles discuss cardio “strain recovery,” stimulant-load buffer, and PCT-adjacent heart support — pure anecdote, no controlled stack trials. forum
- Stack halo: Often credited inside multi-bioregulator kits (heart + vessel + pineal + thymus); single-agent credit is weak when five peptides run together. forum
- Feel character: Little acute kick; quieter cardiac complaints, steadier exertion, or “too subtle / nothing” over weeks if anything. anecdote
- Null outcome is common: Honest community and catalog writeups note “no noticeable change” is fully consistent with sparse human data. forum
- Cardiac remodeling talk: Myocardial recovery / less maladaptive scar framing after stress or injury models — mostly preclinical + anecdote, not human outcome trials on gray-market product. forum
- Fibroblasts (preclinical / hypothesized): AEDR/Cardiogen discussed as shifting cardiac fibroblast behavior and scar-related endpoints; dual talk of cardiomyocyte support vs excess fibroblast maturation in remodeling narratives. Secondary writeups sometimes reverse-claim “stimulate fibroblasts” for ECM repair — treat as contested secondary summary, not a settled human endpoint. animal
- Myocardial culture (preclinical): Chalisova et al. (Adv Gerontol 2009; PMID 20210190): tetrapeptide at ~10⁻¹² M strongly stimulated proliferation in young and old rat myocardial organotypic explants; immunohistochemistry showed decreased p53 expression, framed as less apoptosis in myocardial tissue. animal
- Cytoskeletal protein talk (cell work): Secondary research pages cite short incubations with H-Ala-Glu-Asp-Arg-OH associated with higher expression of actin, vimentin, tubulin, and lamin A/C in cultured systems — mechanistic/secondary, not a human functional trial. lab
- Inflammaging / SASP (review-level): Khavinson et al. 2022 (Cells; PMID 36611900 / PMC9818427) places AEDR tetrapeptide among peptides regulating molecules involved in inflammaging and SASP-forming cells of the cardiovascular system, alongside KED (Vesugen) — mechanistic/review, not a human CV-event trial. trial
- Cardioprotection (patent / rodent): US Patent 7,662,789 (“Peptide substance restoring myocardium function,” Ala-Glu-Asp-Arg) describes cardioprotective activity across rodent models including coronary-artery-ligation infarction, ischemia-reperfusion, adrenaline dystrophy, and arrhythmia — patent material, not peer-reviewed clinical outcomes. animal
- Cardiomyocyte / progenitor interest: Speculative proliferative and progenitor-signaling narratives toward restoring damaged myocardium function appear widely in vendor blogs; hard anchors remain culture/animal. animal
- Tumor-model signals (preclinical): Levdik & Knyazkin (Bull Exp Biol Med 2009; PMID 20396706): rat M-1 sarcoma work reported higher tumor-cell apoptosis, hemorrhagic necrosis, and dose-dependent growth inhibition after Cardiogen injections — mechanism framed as vascular/morphologic, not simple cytostatic; opposite direction from myocardial anti-apoptosis talk. Not cancer therapy. animal
- Prostate fibroblast signaling (cell work): Related short-peptide panels including Cardiogen restored aging prostate-fibroblast signaling-factor expression in culture models — age-biology context, not BPH/cancer treatment. lab
- Gene-expression class halo: Systematic reviews of peptide regulation of gene expression (e.g. Khavinson-line 2021 open-access survey) include Cardiogen among surveyed bioregulators — class context, not a dedicated human CV RCT. trial
- What it is not proven for: No high-quality evidence it treats HF, prevents MI, lowers CV mortality, replaces guideline-directed medical therapy, or “regenerates” human myocardium on a clinical schedule. trial
Doses people talk about
- No validated human dose: Honest dosing guides state explicitly there is no clinical-trial-established human dose; circulating figures are extrapolated from Khavinson bioregulator course culture and research-chem handling convention. forum
- Oral classic (Khavinson-style charts): ~10 mg daily × ~10 consecutive days (~100 mg course total); often empty stomach or sublingual, morning. forum
- Oral higher short block: ~20 mg daily × ~10 days (~200 mg course total) in wellness protocol writeups. forum
- Injectable microdose band: ~200–500 mcg subcutaneous once daily for short consecutive courses — common “microdose” peptide-chart cluster; weekly totals roughly ~1.4–3.5 mg at the top of a multi-week 200–500 mcg ramp. forum
- Injectable community cluster (most-cited low-mg band): ~0.2–2 mg SubQ once daily for ~10–20 days is the range honest community catalogs summarize most often. forum
- Injectable mid–high daily (mixed charts): Some writeups list ~1–5 mg/day oral-or-inject mixed charts; exploring-peptides-style pages cite ~1–5 mg/day oral or inject as “typical research/clinical” figures without a single trial ladder. forum
- Injectable high short IM/SC: ~5–10 mg IM or subq daily for ~5–10 days — less common than oral cytogen-style products and less common than 1–2 mg SC daily research-chem charts. forum
- Intermittent high-dose charts: ~10–20 mg subcutaneous every 3–7 days for ~2–4 weeks (then matching off period in some blogs) — conflicts with daily low-mg bioregulator tradition; treat as vendor-blog variance, not a single standard. forum
- EOD / athlete charts: Occasional ~10 mg every other day SC for “endurance” blocks on product pages — again unstandardized. forum
- Extended vendor blocks: 4–6 weeks at ~10 mg/day oral or SC, or even 6–12 week continuous talk with multi-week breaks — longer than classic 10–20 day bioregulator courses. forum
- Titration charts (20 mg vial): Multi-week ramps e.g. weeks 1–2 ~200 mcg daily → weeks 3–4 ~300 mcg → week 5 ~400 mcg → later ~500 mcg daily over up to ~12 weeks — convenience math on dosage-calculator sites, not trial escalation. forum
- Pepzilla-class secondary bands: Some calculators/guides list dose ranges like ~5–20 mg/day with cycle lengths ~10–30 days — higher than the 0.2–2 mg community-inject cluster; illustrates how divergent secondary sources are. forum
- Course totals: Oral often ~100–200 mg over ~10 days; injectable course totals swing from a few milligrams (microdose 10 days) to tens of milligrams (1–2 mg × 10–20 days) or higher if intermittent 10–20 mg charts are copied. forum
- Route bioavailability debate: Injectable research-chem culture claims superior exposure vs oral capsules (classic peptide GI degradation argument); oral/sublingual remains the historical bioregulator marketing form and most common non-inject path. No head-to-head human PK package settles the fight for pure AEDR. forum
- Uncertainty / chart chaos: Oral cytogen products, sublingual drops, lyophilized “Cardiogen 20 mg” research vials, Chelohart-style heart complexes, and Cardiolax-adjacent names are not automatically the same dose identity; mcg vs mg typos and copy-paste protocol tables are common. forum
- Oral “preventive vs therapeutic” talk: Preventive ~10 mg × 10 days every ~6 months; more aggressive disease-context talk ~20 mg daily × ~20 days every ~3 months — still marketing/community, not Western RCT schedules. forum
- Oral / sublingual product cycles as “10–20 mg per cycle” wording: Some blogs compress the whole course into a single “10–20 mg per cycle” phrase while others mean 10–20 mg *per day* — read labels carefully; these are not the same math. forum
- Framing: Ranges below are community / vendor / secondary-writeup discussion only — not prescriptions, not trial-established human doses, not safety-validated protocols. No Phase 2-style dose exists for gray-market Cardiogen. Chart chaos (mcg vs mg, oral complex vs pure AEDR) is itself a core fact. forum
- Animal / lab notes cited online: Intraperitoneal or in-vivo figures like ~0.1 mcg/kg, ~1–10 µg/kg aging models, ~5–50 µg/kg acute stress models, and cell-culture ~10–100 nM appear on secondary peptide pages — not human conversion recipes. animal
How it may feel
- Days 1–3: Acute experience is mixed, not reliably absent. One 2 mg/day bedtime report described elevated resting heart rate overnight, said earlier timing seemed different, and later stopped on day 12 amid product-identity uncertainty; another commenter described lower heart rate and blood pressure with morning use. These reports do not establish causation or a typical clock. forumanecdote
- Days 4–10: Active window in short-course models — subtle energy, breathing-ease, training-load continuity, or still nothing. Closest hard anchors remain preclinical, not human felt-effect data. forum
- Days 10–20 (typical course end): Checkpoint for steadier exertion tolerance vs “too subtle.” Community courses often stop here by bioregulator convention. forum
- Weeks 2–8 post-course: Residual benefit framed as continuing after blood levels drop — gene-expression narrative, not proven maintenance PK. anecdote
- Months 3–6: Decision to re-run ~2–4×/year (every 3–6 months) rather than open-ended daily use; seasonal spring/fall calendars appear in Russian-style protocol talk. forum
- Extended inject runs (4–6+ weeks): Some gray-market charts push longer daily or EOD inject blocks, or intermittent high-mg every 3–7 days; still anecdotal, with no solid multi-year safety DB. forum
- 12-week microdose ramps: Vendor titration calculators (200→500 mcg daily) stretch far past classic 10–20 day courses; expectation should stay low and confound-aware. forum
- No change: Recheck training load, sleep, BP meds, purity/identity (oral complex vs pure AEDR), COA, and stimulant/stack confounders — not automatic dose mega-escalation. forum
Cycles people discuss
- Oral product courses: Often ~10 days (sometimes 20–30 day capsule guidance on commercial lines). forum
- Extended short inject: ~2–4 weeks or ~4–6 weeks on some research-peptide blogs; still anecdotal. forum
- Intermittent high-mg cycles: 2–4 weeks of every-3–7-day 10–20 mg SC with matching off “to reset receptors” — vendor-blog receptor lore, not measured AEDR tachyphylaxis data. forum
- Off periods / re-runs: Courses every ~3–6 months (~2–4×/year); spring-and-fall seasonal calendars appear in traditional protocol talk. forum
- Preventive vs aggressive calendars (community marketing): Preventive ~every 6 months; more aggressive disease-context talk ~every 3 months — not Western RCT schedules. forum
- Continuous daily open-ended: Less common than GH secretagogues; framed non-standard vs gene-pulse short courses. forum
- 12-week microdose ramps: Calculator-driven continuous daily titration is a gray-market innovation relative to classic 10–20 day blocks. forum
- Classic short blocks: 10–20 consecutive days — dominant Khavinson-style / community convention for bioregulators; rationale borrowed from transient gene-expression signal framing (class literature, not Cardiogen-specific human optimization). forum
- Multi-year safety: No solid multi-year gray-market human safety database; re-runs are practice tradition, not proven maintenance therapy. trial
Timing
- Vendor half-life scatter: Secondary encyclopedic pages quote wildly different figures (e.g. ~30–75 seconds plasma estimates vs multi-hour “bioregulator estimates”) — treat as unverified marketing/secondary numbers, not a single measured human t½. Short ultrapeptide plasma residence is expected class-wise, not Cardiogen-specific proof. forum
- Forum practical timing: Once-daily course charts and every-3–7-day high-mg vendor charts coexist, but no measured AEDR half-life was located; a copied schedule is not evidence of hours-scale elimination or a validated interval. forum
- Why short courses anyway: Bioregulator practice assumes brief exposure triggers gene-expression changes that persist after peptide clears — class convention (sometimes cited via Khavinson & Anisimov 2009-style reviews), not a Cardiogen-specific human PK/PD trial. forum
- Downstream feel: Claimed endurance / cardiac comfort days–weeks after blood levels would have dropped; separates plasma presence from subjective course effect. anecdote
- Oral timing: Often morning, empty stomach or under tongue for sublingual products; some commercial charts allow with food or 5–10 min before meals depending on brand. forum
- Inject timing: Once daily, commonly morning; site rotation (abdomen, thigh, other SC fat); no head-to-head AM/PM outcome data. Community sources typically say do not exceed one dose per 24 hours on daily charts. forum
- PK honesty: Formal human half-life, bioavailability, and clearance packages for gray-market synthetic Cardiogen are sparse to absent; honest research pages often state “not well characterized.” trial
More on what it is
- Why people search it: Longevity and gray-market peptide circles want a “heart-specific” peer next to Vesugen (vessels), Epitalon (pineal), and multi-organ kits — not a mainstream cardiology drug. Hard-training / PED communities add cardio-strain recovery lore. forum
- Cytogen vs complex (critical identity): Pure AEDR lyophilizate (“Cardiogen” research chem) is not the same as organ-extract Cytomax-style “heart” products such as Chelohart (bovine cardiac tissue complex). Community and product lines blur them; sequence identity, dose, and PK are not interchangeable without labels. forum
- Research lens: “Regrows heart muscle,” “cures HF,” or fixed mmHg BP-drop claims need species, pure AEDR vs extract, endpoint, and design checks; tumor-apoptosis papers do not make it oncology therapy; vendor “clinical use in Russia since the 1990s” language often mixes extract-era products with synthetic AEDR. forum
- What it is: Synthetic tetrapeptide Ala-Glu-Asp-Arg (one-letter AEDR; full form often H-Ala-Glu-Asp-Arg-OH); ~489.5 g/mol, formula commonly listed C18H31N7O9; PubChem CID sometimes cited as 11583989 on secondary pages. Khavinson-line short heart bioregulator / Cytogen-class peptide. Research-only outside jurisdictions that regulate older bioregulator products. trial
- Sequence neighbors: Distinct from Cortagen (AEDP), Epitalon (AEDG), Pinealon (EDR), and Vesugen (KED) — shared short-peptide class, different tissue targets and sequences. Vendor “AED” shorthand is incomplete and confusable. trial
- Mechanism talk: Ultrashort-peptide gene-expression / DNA-promoter stories (site-specific DNA binding / endonuclease-modulation narratives in Khavinson-line reviews); dual fibroblast vs cardiomyocyte talk; less adverse scar remodeling; cardiomyocyte proliferative signals in culture; inflammaging/SASP molecule regulation in review-level CV-cell work. trial
- Evidence honesty: Animal and organotypic cardiac work (e.g. myocardial explant cultures, p53 down-shift), US patent cardioprotection claims in rodent models, older Russian bioregulator notes, M-1 sarcoma tumor-modifying animal work, and a 2022 review linking AEDR to CV inflammaging molecules — almost no modern Western RCTs for pure synthetic Cardiogen as sold online. Much of the literature is single-lineage / Russian-language. trial
- Not this: Not a beta-blocker, ACE inhibitor, ARNI, SGLT2, statin, nitrate, GH secretagogue, or drop-in substitute for chest-pain / HF / post-MI workup. Not FDA/EMA-approved for any human indication in Western framing. trial
Stacks
- Heart + vessels classic: Cardiogen + Vesugen (KED) — heart-muscle bioregulator paired with vascular/endothelial bioregulator for full CV longevity talk; often same short-course calendar (e.g. ~10–20 days each) with no fixed mg:mg trial ratio. forum
- Khavinson multi-organ kits: With Epitalon (pineal), Pinealon, Thymalin / Thymogen, Cortagen, Vilon in multi-tissue calendars — single-agent attribution weak. forum
- PCT / immune adjacency: Cardiogen + Thymogen discussed in PED-recovery writeups (cardio support + immune reset lore) — no controlled combo data. forum
- Repair adjacency: Occasional BPC-157 and/or TB-500 co-mention for systemic recovery + heart-specific narrative — confounded multi-peptide runs common in hard-training blogs. forum
- Cartalax co-mention: Community catalogs list Cardiogen + Cartalax as tissue-specific pairing (cardiac + cartilage) — theoretical only. forum
- Epitalon longevity pairing: Broader geroprotection stack (heart-specific + pineal) without controlled combo data. forum
- Mito / longevity lifestyle stacks: Sometimes SS-31, MOTS-c, NAD precursors, CoQ10, or omega-3 — heavily confounded with training and diet; CoQ10/omega-3 appear in “works well with” wellness lists. forum
- Vs other cardiac names: Compared in podcasts/forums to Cardiolax and complex heart bioregulators (extract products such as Chelohart / Cytomax heart complexes) — different identity; do not assume same dose or sequence. forum
- Cytogen vs Cytomax sequencing talk: Some bioregulator calendars sequence synthetic short peptides (Cardiogen) for faster “pulse” then longer extract-complex heart products — brand-dependent, not a trial protocol. forum
- Basics that share credit: Aerobic base, BP basics, sleep, lipid management, and actual cardiology follow-up often explain outcomes more than the peptide alone. forum
- Cardiogen + Vilon: Heart + immune/immune-balance framing in secondary stacking guides. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Redness, irritation, stinging, or mild local reaction with subq — worse with poor technique or contaminated product; most commonly mentioned community event. forum
- Mild systemic: Occasional fatigue, headache, or transient BP fluctuation reported in secondary writeups; stacks and training confound attribution. forum
- Oral GI: Rare digestive discomfort notes; minority and poorly controlled. forum
- Self-treatment risk: Not a substitute for chest pain, arrhythmia, heart failure, post-MI care, or uncontrolled hypertension workup — emergency symptoms need real medicine, not a bioregulator course. forum
- Malignancy / growth caution: Preclinical mix of cardiomyocyte proliferative signals, angiogenesis-style talk, and opposite tumor-cell apoptosis in sarcoma models fuels theoretical cancer debates; active malignancy is a common “avoid / physician-only” caution in secondary guides. forum
- Angiogenesis theoretical concern: Some encyclopedic peptide pages flag theoretical tumor-support risk if angiogenic claims are real — unproven in humans either direction. forum
- Source quality: Gray-market contamination, under/over-label, oral-complex vs pure AEDR mislabel, and Chelohart/Cardiogen name confusion are structural risks; demand COA (HPLC/MS) talk is standard community advice, not a guarantee. forum
- Drug interaction gap: No robust modern interaction table; “plays fine with heart meds” claims in blogs are not controlled data — cardiology meds stay under physician control. forum
- Half-life claim noise: Do not treat tens-of-seconds vs multi-hour vendor half-life numbers as settled PK. forum
- Dose-chart hazards: Copying intermittent 10–20 mg every 3–7 days charts onto daily microdose math (or vice versa), and confusing oral 10 mg/day with injectable 10 mg/day, are frequent error modes. forum
- Evidence sparsity: No solid modern Western human safety DB, long-term AEDR RCT package, or trial-established dose for research-chem product; human tolerability is essentially uncharacterized in controlled trials. trial
- Not risk-free: Missing sides in one log ≠ safety proof; research-chemical and research-only framing still apply. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.